BrightPath Biotherapeutics Co., Ltd.
4594
Rank in Stocks
#24373
BrightPath Biotherapeutics Co., Ltd. specializes in the development of... BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
Share Price
$0.24052689
Last synced: 2026-11-10
Market Cap
$33.41M
Change (1 day)
2.70%
Change (1 year)
-40.05%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BrightPath Biotherapeutics Co., Ltd. (4594)
Category
Healthcare
EPS for BrightPath Biotherapeutics Co., Ltd. (4594)
EPS as of June 2026 TTM: $-0.08
According to BrightPath Biotherapeutics Co., Ltd.'s latest financial reports, its current EPS (TTM) is $-0.08. At the end of 2025 the company had an EPS of $-0.09, an increase over its 2024 EPS of $-0.12.
EPS history for BrightPath Biotherapeutics Co., Ltd. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.08 | -10.00% |
| 2025 | $-0.09 | -21.70% |
| 2024 | $-0.12 | -35.84% |
| 2023 | $-0.19 | -20.04% |
| 2022 | $-0.23 | -28.13% |
| 2021 | $-0.33 | -20.63% |
| 2020 | $-0.41 | 1.51% |
| 2019 | $-0.41 | 4.33% |
| 2018 | $-0.39 | 32.09% |
| 2017 | $-0.29 | -6.28% |
| 2016 | $-0.31 | 82.54% |
| 2015 | $-0.17 | -1,309.86% |
| 2014 | $0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -19,433.33% |
US
|
|
| $-7.07 | 8,628.40% |
US
|
|
| $-5.29 | 6,430.86% |
AU
|
|
| $12.88 | -16,001.36% |
BE
|
|
| $21.56 | -26,717.28% |
NL
|
Questions about BrightPath Biotherapeutics Co., Ltd.'s earnings per share (EPS)
What is BrightPath Biotherapeutics Co., Ltd.'s earnings per share (EPS)?
BrightPath Biotherapeutics Co., Ltd.'s earnings per share (EPS) over the last twelve months is $-0.08, as of Jun 2026.
What was BrightPath Biotherapeutics Co., Ltd.'s earnings per share (EPS) in 2025?
In 2025, BrightPath Biotherapeutics Co., Ltd.'s earnings per share (EPS) was $-0.09, compared with $-0.12 in 2024.
How has BrightPath Biotherapeutics Co., Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, BrightPath Biotherapeutics Co., Ltd.'s earnings per share (EPS) was highest in 2025 ($-0.09) and lowest in 2020 ($-0.41).
How does BrightPath Biotherapeutics Co., Ltd.'s earnings per share (EPS) compare with similar companies?
BrightPath Biotherapeutics Co., Ltd.'s earnings per share (EPS) ($-0.08) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.